drugset
drugset / Trial / NCT00750360

Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.

NCT00750360 ↗

Phase 4 Completed 883 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The present study collects data on safety and reactogenicity of the vaccine in the local target population (600 or more subjects) as per the requirement of Korean Food and Drugs Administration (KFDA).

Timeline

Start
2003-10-03
Primary completion
2007-12-01
Completion
2007-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject FluarixTM Vaccine — —

Indications

influenza